Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6609 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-02 (scientistlive.com)
Alzheimer's medication approved by European Commission | Scientist Live
The medication designed for mild cognitive impairment or mild dementia due to Alzheimer's.
Read more
2025-05-02 (devdiscourse.com)
Global Health Landscape: From Vaccine Innovation to Regulatory Battles | Science-Environment
Recent health news spotlights include Cardinal Health's robust growth forecast despite tariffs, CVS's strategy shifts, Biogen's resilience in rare disease markets, and novel treatments advancements by J&J. Additionally, regulatory and funding challenges faced by WHO and the U.S. emphasize the complex dynamics shaping global healthcare.
Read more
2025-04-29 (thepharma.media)
Biogen registered in the United Kingdom a drug against ataxia Friedreich - .Media
Skyclarys (omelloxolon) provides neurological improvement in patients with Friedreich ataxia compared to placebo.
Read more
2025-04-24 (pmlive.com)
Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia -
The neurodegenerative disease affects at least one in every 50,000 people in the UK
Read more
2025-04-23 (practicalneurology.com)
Investigational Tau-Targeting Therapy for Alzheimer Disease Receives FDA Fast Track Designation - -
The Food and Drug Administration (FDA) has granted Fast Track Designation to BIIB080 (Biogen, Cambridge, MA), an investigational antisense oligonucleotide…
Read more
2025-04-17 (pharmvestnik.ru)
The European Commission approved the first drug for the treatment of Alzheimer's disease »Pharmaceutical
Leqembi registration application considered more than two years
Read more
2025-04-16 (kdhnews.com)
European regulators OK Alzheimer's treatment Leqembi after initial doubts | Nation | .com
European regulators have finally approved the Alzheimer's treatment Leqembi after an advisory committee initially rejected the drug last summer. The infused treatment from Japanese drugmaker Eisai and Biogen received approval
Read more
2025-04-16 (jurnalul.ro)
A new medicine against Alzheimer's disease receives a green wave from the European authorities
The European Commission announces on Wednesday that it has authorized a treatment for "treating mild cognitive disorder" in certain patients with Alzheimer's disease, according to Le Figaro.
Read more
2025-04-16 (nikkeibp.co.jp)
Biogen Acquires Fast Track Designation from FDA for Tau-Targeted Antisense Drug BIIB080 for Alzheimer's Disease:
On April 2, 2025, Biogen Inc. announced that BIIB080, an antisense oligonucleotide (ASO) drug targeting tau, has received fast track designation from the US Food and Drug Administration (FDA) for Alzheimer's disease (AD).
Read more
2025-04-16 (eleconomista.es)
Brussels authorizes 'Leqembi', the first treatment that slows the Alzheimer's from Eisai and Biogen
The European Commission authorizes Leqembi, the first treatment that slows down the mild cognitive deterioration of Alzheimer's during the early stages of the disease. Brussels gave yesterday the final approval for the use in the European Union of Lecanemab, marketed by EISAI and Biogen as Leqembi.
Read more
2025-04-14 (marketaccesstoday.com)
Eisai and Biogen Await Final EU Decision on Alzheimer's Drug Lecanemab -
Eisai Co., Ltd. and Biogen Inc. announced progress in the regulatory evaluation of lecanemab, a treatment for early-stage Alzheimer's Disease, by the
Read more
2025-04-08 (lifesciencesweden.se)
Tau-targeted Alzheimer's drug gets Fast Track designation in the USA
Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Read more